BIO Comments on FDA Draft Guidance on Testing of Retroviral Vector-Based Human Gene Therapy Products
November 14, 2018
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-Up.
BIO agrees with most recommendations in the draft guidance on product testing for replication competent retrovirus (RCR). In particular, BIO commends the FDA for inviting the gene therapy community to publish findings of relevant studies, which will benefit and advance the field.
BIO suggests FDA convene a public workshop with industry, academia, and other stakeholders to discuss current scientific data regarding RCR in gene therapy applications. BIO would be happy to help FDA with this effort.
In addition, BIO suggested passages in the draft guidance that could be clarified.
Download Full Comments Below
FINAL BIO Letter Testing Of Retroviral Vector-Based GT Products For RCR 12-10-18
One thing that we can all agree on is the need to give our children a fighting chance so they can lead long and productive lives. That is why it is critical to pass the bipartisan Give Kids a Chance Act and ensure the Pediatric Priority Review…
Dear Colleagues, This month marks my one-year anniversary as BIO's CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request for Comments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-Up.
BIO agrees with most recommendations in the draft guidance on product testing for replication competent retrovirus (RCR). In particular, BIO commends the FDA for inviting the gene therapy community to publish findings of relevant studies, which will benefit and advance the field.
BIO suggests FDA convene a public workshop with industry, academia, and other stakeholders to discuss current scientific data regarding RCR in gene therapy applications. BIO would be happy to help FDA with this effort.
In addition, BIO suggested passages in the draft guidance that could be clarified.